VIVS Overview

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company's 3D human tissue platform is multifaceted. The Company has expertise in 3D organoids, such as spheroids, and has made advances in proprietary cell culture techniques including ratios, components and conditions.

Wall Street analysts forecast VIVS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIVS is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

VivoSim Labs Inc revenue for the last quarter amounts to 26.00K USD, increased 8.33

VivoSim Labs Inc. EPS for the last quarter amounts to -1.03 USD, decreased -55.02

VivoSim Labs Inc (VIVS) has 5 emplpoyees as of March 13 2026.

Today VIVS has the market capitalization of 4.85M USD.